Table 4. Percentage of validated, common CpG markers based on the coverage of 95% credible intervals inferred from the training data, by sex and marker type.

The outcome of interest for validation was the estimated difference in methylation. For Pan T markers, results are summarised by individual cell type and jointly, the latter corresponding to both CD4⁺T and CD8⁺T differences being validated for the same marker.

	Differential methylation		Methylation state
Marker panel	Female	Male	Female	Male
CD19+B	36.9	25.8	99.9	99.7
CD4+T	37.7	53.9	97.6	100
CD8+T	38.1	63.4	98.6	99.7
PanT	21.4	31.6	99.7	99.5
Pan T: CD4+T only	46.7	54.5	100	100
Pan T: CD8+T only	42.7	41.1	99.7	99.5